Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9.
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Most Important
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Somewhat Important
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Important
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Not very important
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Not important at all
Update for Pharmacists Administering Authority for Immunizations by lowering age requirements for an immunization from age 14 to age 9. Neutral
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Most Important
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Somewhat Important
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Important
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Not very important
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Not important at all
Promote a realistic and professional sustainable fee by the MCOs for community pharmacies Neutral
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.)
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Most Important
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Somewhat Important
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Important
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Not very important
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Not important at all
Continuation of support of 2016's HB 458 (Mail Order and Specialty Drugs & Cessation of mail order promotion by the MCOs.) Neutral
Mail Order (stand alone bill)
Mail Order (stand alone bill) Most Important
Mail Order (stand alone bill) Somewhat Important
Mail Order (stand alone bill) Important
Mail Order (stand alone bill) Not very important
Mail Order (stand alone bill) Not important at all
Mail Order (stand alone bill) Neutral
Specialty Drugs (stand alone bill)
Specialty Drugs (stand alone bill) Most Important
Specialty Drugs (stand alone bill) Somewhat Important
Specialty Drugs (stand alone bill) Important
Specialty Drugs (stand alone bill) Not very important
Specialty Drugs (stand alone bill) Not important at all
Specialty Drugs (stand alone bill) Neutral
Patient care issues
Patient care issues Most Important
Patient care issues Somewhat Important
Patient care issues Important
Patient care issues Not very important
Patient care issues Not important at all
Patient care issues Neutral
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example.
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Most Important
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Somewhat Important
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Important
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Not very important
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Not important at all
Support legislation that would require the MCOs and insurances providers where applicable to reimburse the pharmacist at a provider rate and method, e.g., for Naloxone initiation therapy as one example. Neutral